Oncology The future of oncology is adaptive: What ESMO 2026 revealed ... Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.
Oncology How precision medicine treats an overlooked clinical variabl... In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.
Oncology How AI is advancing patient subgroup identification in oncol... With the advent of AI, it’s now possible to enrich clinical trials for patient subgroups more precisely than ever before.
Oncology Why precision biomarkers will change the future of breast ca... Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.
R&D Clinical Trials Round-Up: July/August 2026 While the volume of announcements hit a mid-year slump, July and August still produced an exciting array of updates across the drug development arena.
Oncology Sponsored Establishing ctDNA as a validated primary surrogate endpoint Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.